M	0	1	B-Gene_or_gene_product
-	1	2	I-Gene_or_gene_product
CSF	2	5	I-Gene_or_gene_product
signals	6	13	O
through	14	21	O
the	22	25	O
MAPK	26	30	B-Gene_or_gene_product
/	30	31	O
ERK	31	34	B-Gene_or_gene_product
pathway	35	42	O
via	43	46	O
Sp1	47	50	B-Gene_or_gene_product
to	51	53	O
induce	54	60	O
VEGF	61	65	B-Gene_or_gene_product
production	66	76	O
and	77	80	O
induces	81	88	O
angiogenesis	89	101	O
in	102	104	O
vivo	105	109	O
.	109	110	O

BACKGROUND	112	122	O
:	122	123	O
M	124	125	B-Gene_or_gene_product
-	125	126	I-Gene_or_gene_product
CSF	126	129	I-Gene_or_gene_product
recruits	130	138	O
mononuclear	139	150	B-Cell
phagocytes	151	161	I-Cell
which	162	167	O
regulate	168	176	O
processes	177	186	O
such	187	191	O
as	192	194	O
angiogenesis	195	207	O
and	208	211	O
metastases	212	222	O
in	223	225	O
tumors	226	232	B-Pathological_formation
.	232	233	O

VEGF	234	238	B-Gene_or_gene_product
is	239	241	O
a	242	243	O
potent	244	250	O
activator	251	260	O
of	261	263	O
angiogenesis	264	276	O
as	277	279	O
it	280	282	O
promotes	283	291	O
endothelial	292	303	B-Cell
cell	304	308	I-Cell
proliferation	309	322	O
and	323	326	O
new	327	330	O
blood	331	336	B-Multi-tissue_structure
vessel	337	343	I-Multi-tissue_structure
formation	344	353	O
.	353	354	O

Previously	355	365	O
,	365	366	O
we	367	369	O
reported	370	378	O
that	379	383	O
in	384	386	O
vitro	387	392	O
M	393	394	B-Gene_or_gene_product
-	394	395	I-Gene_or_gene_product
CSF	395	398	I-Gene_or_gene_product
induces	399	406	O
the	407	410	O
expression	411	421	O
of	422	424	O
biologically	425	437	O
-	437	438	O
active	438	444	O
VEGF	445	449	B-Gene_or_gene_product
from	450	454	O
human	455	460	B-Organism
monocytes	461	470	B-Cell
.	470	471	O

METHODOLOGY	472	483	O
AND	484	487	O
RESULTS	488	495	O
:	495	496	O
In	497	499	O
this	500	504	O
study	505	510	O
,	510	511	O
we	512	514	O
demonstrate	515	526	O
the	527	530	O
molecular	531	540	O
mechanism	541	550	O
of	551	553	O
M	554	555	B-Gene_or_gene_product
-	555	556	I-Gene_or_gene_product
CSF	556	559	I-Gene_or_gene_product
-	559	560	O
induced	560	567	O
VEGF	568	572	B-Gene_or_gene_product
production	573	583	O
.	583	584	O

Using	585	590	O
a	591	592	O
construct	593	602	O
containing	603	613	O
the	614	617	O
VEGF	618	622	B-Gene_or_gene_product
promoter	623	631	B-DNA_domain_or_region
linked	632	638	O
to	639	641	O
a	642	643	O
luciferase	644	654	B-Gene_or_gene_product
reporter	655	663	O
,	663	664	O
we	665	667	O
found	668	673	O
that	674	678	O
a	679	680	O
mutation	681	689	O
reducing	690	698	O
HIF	699	702	B-Gene_or_gene_product
binding	703	710	O
to	711	713	O
the	714	717	O
VEGF	718	722	B-Gene_or_gene_product
promoter	723	731	B-DNA_domain_or_region
had	732	735	O
no	736	738	O
significant	739	750	O
effect	751	757	O
on	758	760	O
luciferase	761	771	B-Gene_or_gene_product
production	772	782	O
induced	783	790	O
by	791	793	O
M	794	795	B-Gene_or_gene_product
-	795	796	I-Gene_or_gene_product
CSF	796	799	I-Gene_or_gene_product
stimulation	800	811	O
.	811	812	O

Further	813	820	O
analysis	821	829	O
revealed	830	838	O
that	839	843	O
M	844	845	B-Gene_or_gene_product
-	845	846	I-Gene_or_gene_product
CSF	846	849	I-Gene_or_gene_product
induced	850	857	O
VEGF	858	862	B-Gene_or_gene_product
through	863	870	O
the	871	874	O
MAPK	875	879	B-Gene_or_gene_product
/	879	880	O
ERK	880	883	B-Gene_or_gene_product
signaling	884	893	O
pathway	894	901	O
via	902	905	O
the	906	909	O
transcription	910	923	O
factor	924	930	O
,	930	931	O
Sp1	932	935	B-Gene_or_gene_product
.	935	936	O

Thus	937	941	O
,	941	942	O
inhibition	943	953	O
of	954	956	O
either	957	963	O
ERK	964	967	B-Gene_or_gene_product
or	968	970	O
Sp1	971	974	B-Gene_or_gene_product
suppressed	975	985	O
M	986	987	B-Gene_or_gene_product
-	987	988	I-Gene_or_gene_product
CSF	988	991	I-Gene_or_gene_product
-	991	992	O
induced	992	999	O
VEGF	1000	1004	B-Gene_or_gene_product
at	1005	1007	O
the	1008	1011	O
mRNA	1012	1016	O
and	1017	1020	O
protein	1021	1028	O
level	1029	1034	O
.	1034	1035	O

M	1036	1037	B-Gene_or_gene_product
-	1037	1038	I-Gene_or_gene_product
CSF	1038	1041	I-Gene_or_gene_product
also	1042	1046	O
induced	1047	1054	O
the	1055	1058	O
nuclear	1059	1066	B-Cellular_component
localization	1067	1079	O
of	1080	1082	O
Sp1	1083	1086	B-Gene_or_gene_product
,	1086	1087	O
which	1088	1093	O
was	1094	1097	O
blocked	1098	1105	O
by	1106	1108	O
ERK	1109	1112	B-Gene_or_gene_product
inhibition	1113	1123	O
.	1123	1124	O

Finally	1125	1132	O
,	1132	1133	O
mutating	1134	1142	O
the	1143	1146	O
Sp1	1147	1150	B-Gene_or_gene_product
binding	1151	1158	B-DNA_domain_or_region
sites	1159	1164	I-DNA_domain_or_region
within	1165	1171	O
the	1172	1175	O
VEGF	1176	1180	B-Gene_or_gene_product
promoter	1181	1189	B-DNA_domain_or_region
or	1190	1192	O
inhibiting	1193	1203	O
ERK	1204	1207	B-Gene_or_gene_product
decreased	1208	1217	O
VEGF	1218	1222	B-Gene_or_gene_product
promoter	1223	1231	B-DNA_domain_or_region
activity	1232	1240	O
in	1241	1243	O
M	1244	1245	B-Gene_or_gene_product
-	1245	1246	I-Gene_or_gene_product
CSF	1246	1249	I-Gene_or_gene_product
-	1249	1250	O
treated	1250	1257	O
human	1258	1263	B-Organism
monocytes	1264	1273	B-Cell
.	1273	1274	O

To	1275	1277	O
evaluate	1278	1286	O
the	1287	1290	O
biological	1291	1301	O
significance	1302	1314	O
of	1315	1317	O
M	1318	1319	B-Gene_or_gene_product
-	1319	1320	I-Gene_or_gene_product
CSF	1320	1323	I-Gene_or_gene_product
induced	1324	1331	O
VEGF	1332	1336	B-Gene_or_gene_product
production	1337	1347	O
,	1347	1348	O
we	1349	1351	O
used	1352	1356	O
an	1357	1359	O
in	1360	1362	O
vivo	1363	1367	O
angiogenesis	1368	1380	O
model	1381	1386	O
to	1387	1389	O
illustrate	1390	1400	O
the	1401	1404	O
ability	1405	1412	O
of	1413	1415	O
M	1416	1417	B-Gene_or_gene_product
-	1417	1418	I-Gene_or_gene_product
CSF	1418	1421	I-Gene_or_gene_product
to	1422	1424	O
recruit	1425	1432	O
mononuclear	1433	1444	B-Cell
phagocytes	1445	1455	I-Cell
,	1455	1456	O
increase	1457	1465	O
VEGF	1466	1470	B-Gene_or_gene_product
levels	1471	1477	O
,	1477	1478	O
and	1479	1482	O
enhance	1483	1490	O
angiogenesis	1491	1503	O
.	1503	1504	O

Importantly	1505	1516	O
,	1516	1517	O
the	1518	1521	O
addition	1522	1530	O
of	1531	1533	O
a	1534	1535	O
neutralizing	1536	1548	O
VEGF	1549	1553	B-Gene_or_gene_product
antibody	1554	1562	O
abolished	1563	1572	O
M	1573	1574	B-Gene_or_gene_product
-	1574	1575	I-Gene_or_gene_product
CSF	1575	1578	I-Gene_or_gene_product
-	1578	1579	O
induced	1579	1586	O
blood	1587	1592	B-Multi-tissue_structure
vessel	1593	1599	I-Multi-tissue_structure
formation	1600	1609	O
.	1609	1610	O

CONCLUSION	1611	1621	O
:	1621	1622	O
These	1623	1628	O
data	1629	1633	O
delineate	1634	1643	O
an	1644	1646	O
ERK	1647	1650	B-Gene_or_gene_product
-	1650	1651	O
and	1652	1655	O
Sp1	1656	1659	B-Gene_or_gene_product
-	1659	1660	O
dependent	1660	1669	O
mechanism	1670	1679	O
of	1680	1682	O
M	1683	1684	B-Gene_or_gene_product
-	1684	1685	I-Gene_or_gene_product
CSF	1685	1688	I-Gene_or_gene_product
induced	1689	1696	O
VEGF	1697	1701	B-Gene_or_gene_product
production	1702	1712	O
and	1713	1716	O
demonstrate	1717	1728	O
for	1729	1732	O
the	1733	1736	O
first	1737	1742	O
time	1743	1747	O
the	1748	1751	O
ability	1752	1759	O
of	1760	1762	O
M	1763	1764	B-Gene_or_gene_product
-	1764	1765	I-Gene_or_gene_product
CSF	1765	1768	I-Gene_or_gene_product
to	1769	1771	O
induce	1772	1778	O
angiogenesis	1779	1791	O
via	1792	1795	O
VEGF	1796	1800	B-Gene_or_gene_product
in	1801	1803	O
vivo	1804	1808	O
.	1808	1809	O

